OPKO Health, Inc. (OPK)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 27/100 (MEDIUM), 33.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 10.69% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- OPKO Health (OPK) Sells BioReference Assets On A Valuation Story That Still Divides
- Is OPKO Health (OPK) Pricing In Too Much For Sales?
- OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
- Labcorp outlays up to $872m to acquire BioReference’s laboratory assets
- Labcorp to buy BioReference assets for up to $872M
- Opko Health stock soars on $722M BioReference asset sale
- Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
- BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for OPKO Health, Inc..
Full OPK Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.